Nivolumab History and Updates

250 events · 2005 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

154
FDA Approvals
2
Label Revisions
5,289
Trial Milestones
10
Pivotal Publications
Nivolumab — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033203420352036Trial: NCT07176975 2027-08-03 → 2029-01-15 (primary completion)Trial: NCT07644312 2027-03-01 → 2033-03-01 (primary completion)Trial: NCT07369791 2026-12-31 → 2035-12-31 (primary completion)Trial: NCT07572123 2026-12-04 → 2029-03-31 (primary completion)Trial: NCT07459543 2026-11-15 → 2029-05-26 (primary completion)Trial: NCT07631325 2026-10-31 → 2028-07-31 (primary completion)Trial: NCT07689175 2026-10-31 → 2031-10-31 (primary completion)Trial: NCT07551583 2026-10-01 → 2030-12-31 (primary completion)Trial: NCT07679841 2026-09-30 → 2029-09-30 (primary completion)Trial: NCT07576725 2026-09-01 → 2029-08-31 (primary completion)Trial: NCT07541170 2026-09-01 → 2032-01-31 (primary completion)Trial: NCT07430202 2026-08-31 → 2030-08-31 (primary completion)Trial: NCT07694986 2026-08-31 → 2029-08-31 (primary completion)Trial: NCT07444619 2026-08-31 → 2031-12-31 (primary completion)Trial: NCT06319196 2026-08-27 → 2027-02-15 (primary completion)Trial: NCT07700979 2026-08-20 → 2029-08-18 (primary completion)Trial: NCT06365619 2026-07-31 → 2027-08-31 (primary completion)Trial: NCT07355205 2026-07-31 → 2032-07-31 (primary completion)Trial: NCT07546812 2026-07-31 → 2030-01-31 (primary completion)Trial: NCT07460765 2026-07-31 → 2030-04-30 (primary completion)Trial: NCT07281924 2026-07-31 → 2030-12-31 (primary completion)Trial: NCT07645118 2026-07-31 → 2028-12-31 (primary completion)Trial: NCT07492680 2026-07-17 → 2032-05-20 (primary completion)Trial: NCT06639607 2026-06-30 → 2031-08-31 (primary completion)Trial: NCT07518043 2026-06-30 → 2027-08-12 (primary completion)Trial: NCT07383441 2026-06-10 → 2033-01-31 (primary completion)Trial: NCT07494435 2026-06-01 → 2028-06-01 (primary completion)Trial: NCT07476326 2026-06-01 → 2027-08-16 (primary completion)Trial: NCT07529873 2026-05-31 → 2030-04-30 (primary completion)Trial: NCT07420439 2026-05-15 → 2028-08-15 (primary completion)Trial: NCT07514767 2026-05-01 → 2028-09-30 (primary completion)Trial: NCT07501117 2026-05-01 → 2029-06-01 (primary completion)Trial: NCT07510334 2026-05-01 → 2033-08-01 (primary completion)Trial: NCT07338981 2026-04-30 → 2030-12-31 (primary completion)Trial: NCT07527858 2026-04-30 → 2028-12-31 (primary completion)Trial: NCT07188896 2026-04-29 → 2029-11-30 (primary completion)Trial: NCT07392892 2026-04-28 → 2031-07-22 (primary completion)Trial: NCT07319195 2026-04-27 → 2028-04-30 (primary completion)Trial: NCT07504796 2026-04-13 → 2029-05-31 (primary completion)Trial: NCT07532902 2026-04-07 → 2029-04-30 (primary completion)Trial: NCT07128680 2026-04-01 → 2028-08-25 (primary completion)Trial: NCT07075120 2026-04-01 → 2027-08-01 (primary completion)Trial: NCT07187869 2026-03-31 → 2027-04-07 (primary completion)Trial: NCT07210632 2026-03-30 → 2030-03-30 (primary completion)Trial: NCT07563738 2026-03-27 → 2029-09-30 (primary completion)Trial: NCT07293351 2026-03-26 → 2029-11-28 (primary completion)Trial: NCT07401875 2026-03-24 → 2027-11-30 (primary completion)Trial: NCT07405164 2026-03-23 → 2034-01-14 (primary completion)Trial: NCT07219459 2026-03-19 → 2029-09-30 (primary completion)Trial: NCT07221149 2026-03-13 → 2030-11-08 (primary completion)Trial: NCT06863311 2026-03-13 → 2027-12-31 (primary completion)Trial: NCT07485166 2026-03-12 → 2026-09-12 (primary completion)Trial: NCT07404332 2026-02-28 → 2028-02-28 (primary completion)Trial: NCT07432295 2026-02-28 → 2030-03-31 (primary completion)Trial: NCT07394062 2026-02-28 → 2027-08-31 (primary completion)Trial: NCT07166406 2026-02-26 → 2029-03-10 (primary completion)Trial: NCT06999980 2026-02-09 → 2028-03-31 (primary completion)Trial: NCT07398937 2026-02-05 → 2027-12-31 (primary completion)Trial: NCT07325136 2026-02-03 → 2029-04-23 (primary completion)Trial: NCT07431281 2026-02-03 → 2029-08-16 (primary completion)Trial: NCT07328087 2026-02-02 → 2030-12-02 (primary completion)Trial: NCT07403877 2026-02-01 → 2031-12-31 (primary completion)Trial: NCT07216833 2026-01-31 → 2027-07-31 (primary completion)Trial: NCT07276373 2026-01-16 → 2026-09-30 (primary completion)Trial: NCT07195695 2026-01-16 → 2032-02-26 (primary completion)Trial: NCT07230613 2026-01-12 → 2027-12-31 (primary completion)Trial: NCT06968988 2026-01-05 → 2029-02-12 (primary completion)Trial: NCT07221734 2025-12-29 → 2027-04-30 (primary completion)Trial: NCT06963905 2025-12-29 → 2030-12-31 (primary completion)Trial: NCT07017816 2025-12-16 → 2028-05-01 (primary completion)Trial: NCT07196384 2025-12-15 → 2026-10-30 (primary completion)Trial: NCT07226856 2025-12-12 → 2028-12-01 (primary completion)Trial: NCT06908993 2025-12-09 → 2028-03-15 (primary completion)Trial: NCT06346197 2025-12-08 → 2028-05-15 (primary completion)Trial: NCT07526961 2025-12-01 → 2026-01-20 (primary completion)Trial: NCT07233668 2025-12-01 → 2028-10-01 (primary completion)Trial: NCT06816927 2025-11-28 → 2029-06-01 (primary completion)Trial: NCT07334119 2025-11-25 → 2027-01-31 (primary completion)Trial: NCT07176650 2025-11-25 → 2026-12-31 (primary completion)Trial: NCT07223411 2025-11-19 → 2028-11-01 (primary completion)Trial: NCT06948448 2025-11-18 → 2028-02-15 (primary completion)Trial: NCT07223424 2025-11-04 → 2030-11-30 (primary completion)Trial: NCT06794229 2025-10-30 → 2028-06-06 (primary completion)Trial: NCT07155317 2025-10-29 → 2026-12-31 (primary completion)Trial: NCT05717140 2025-10-28 → 2026-01-28 (primary completion)Trial: NCT07246863 2025-10-07 → 2029-10-01 (primary completion)Trial: NCT07174453 2025-10-07 → 2027-10-01 (primary completion)Trial: NCT07028125 2025-10-01 → 2028-10-31 (primary completion)Trial: NCT07152678 2025-09-30 → 2027-09-30 (primary completion)Trial: NCT06946797 2025-09-19 → 2027-02-05 (primary completion)Trial: NCT06410534 2025-09-09 → 2025-09-09 (primary completion)Trial: NCT06941857 2025-09-04 → 2028-12-31 (primary completion)Trial: NCT07147101 2025-09-01 → 2028-09-01 (primary completion)Trial: NCT06624475 2025-08-21 → 2028-05-31 (primary completion)Trial: NCT06866262 2025-08-15 → 2031-08-01 (primary completion)Trial: NCT07011550 2025-08-15 → 2028-07-01 (primary completion)Trial: NCT07013565 2025-08-07 → 2029-07-01 (primary completion)Trial: NCT06712927 2025-08-06 → 2026-11-30 (primary completion)Trial: NCT06624644 2025-08-06 → 2029-02-28 (primary completion)Trial: NCT07092670 2025-08-04 → 2028-08-01 (primary completion)Trial: NCT07209059 2025-07-29 → 2027-12-31 (primary completion)Trial: NCT07000149 2025-07-28 → 2030-02-21 (primary completion)Trial: NCT07031765 2025-07-25 → 2030-12-31 (primary completion)Trial: NCT07061379 2025-07-24 → 2027-06-30 (primary completion)Trial: NCT06794775 2025-07-10 → 2032-04-15 (primary completion)Trial: NCT06767956 2025-06-30 → 2027-04-30 (primary completion)Trial: NCT05733689 2025-06-27 → 2027-06-30 (primary completion)Trial: NCT06896110 2025-06-05 → 2027-03-31 (primary completion)Trial: NCT07542262 2025-06-03 → 2028-03-30 (primary completion)Trial: NCT06163820 2025-05-31 → 2026-01-30 (primary completion)Trial: NCT06364917 2025-05-30 → 2027-04-27 (primary completion)Trial: NCT07141563 2025-05-26 → 2025-11-18 (primary completion)Trial: NCT06889493 2025-05-19 → 2030-06-01 (primary completion)Trial: NCT07050043 2025-05-19 → 2030-12-31 (primary completion)Trial: NCT06934057 2025-05-16 → 2028-04-30 (primary completion)Trial: NCT06823479 2025-05-14 → 2029-02-28 (primary completion)Trial: NCT07091695 2025-05-11 → 2025-11-06 (primary completion)Trial: NCT06683755 2025-05-01 → 2030-08-16 (primary completion)Trial: NCT06983210 2025-05-01 → 2027-03-01 (primary completion)Trial: NCT06800339 2025-04-22 → 2028-03-31 (primary completion)Trial: NCT06984146 2025-04-15 → 2028-01-31 (primary completion)Trial: NCT07100704 2025-04-15 → 2028-04-14 (primary completion)Trial: NCT06731270 2025-04-09 → 2027-01-01 (primary completion)Trial: NCT06712875 2025-04-01 → 2028-12-31 (primary completion)Trial: NCT06880549 2025-03-25 → 2029-01-10 (primary completion)Trial: NCT06764771 2025-03-25 → 2027-10-15 (primary completion)Trial: NCT06245356 2025-03-21 → 2026-10-22 (primary completion)Trial: NCT06708949 2025-03-20 → 2026-12-15 (primary completion)Trial: NCT06534190 2025-03-11 → 2028-11-30 (primary completion)Trial: NCT06745076 2025-03-06 → 2032-01-03 (primary completion)Trial: NCT06901817 2025-03-01 → 2027-11-30 (primary completion)Trial: NCT06523621 2025-02-28 → 2026-03-21 (primary completion)Trial: NCT06561087 2025-02-27 → 2027-05-30 (primary completion)Trial: NCT07084610 2025-02-25 → 2027-07-31 (primary completion)Trial: NCT06646276 2025-02-25 → 2028-04-06 (primary completion)Trial: NCT06697197 2025-02-17 → 2029-01-04 (primary completion)Trial: NCT06926790 2025-02-17 → 2030-03-31 (primary completion)Trial: NCT06618287 2025-02-04 → 2031-02-26 (primary completion)Trial: NCT06743126 2025-01-14 → 2028-01-31 (primary completion)Trial: NCT06692491 2025-01-01 → 2027-12-31 (primary completion)Trial: NCT06587451 2024-12-19 → 2026-01-23 (primary completion)Trial: NCT06581406 2024-12-17 → 2030-01-31 (primary completion)Trial: NCT06715241 2024-12-11 → 2030-12-31 (primary completion)Trial: NCT06632327 2024-12-11 → 2029-04-30 (primary completion)Trial: NCT06504615 2024-12-10 → 2028-08-31 (primary completion)Trial: NCT06534983 2024-12-09 → 2027-11-10 (primary completion)Trial: NCT06519682 2024-12-06 → 2026-12-31 (primary completion)Trial: NCT06499298 2024-12-03 → 2025-04-16 (primary completion)Trial: NCT05457959 2024-12-01 → 2029-12-01 (primary completion)Trial: NCT07079644 2024-11-29 → 2025-03-31 (primary completion)Trial: NCT05647265 2024-11-27 → 2026-12-15 (primary completion)Trial: NCT07215962 2024-11-22 → 2025-07-01 (primary completion)Trial: NCT06682728 2024-11-15 → 2026-12-01 (primary completion)Trial: NCT06325683 2024-11-08 → 2028-07-15 (primary completion)Trial: NCT05629546 2024-11-06 → 2029-02-28 (primary completion)Trial: NCT07024862 2024-10-24 → 2025-06-30 (primary completion)Trial: NCT06490536 2024-10-22 → 2026-03-01 (primary completion)Trial: NCT06544655 2024-10-10 → 2027-10-14 (primary completion)Trial: NCT06561386 2024-10-07 → 2030-07-30 (primary completion)Trial: NCT06246916 2024-09-09 → 2027-03-22 (primary completion)Trial: NCT06735781 2024-09-05 → 2024-10-01 (primary completion)Trial: NCT06572722 2024-09-01 → 2026-09-01 (primary completion)Trial: NCT06871007 2024-09-01 → 2029-09-01 (primary completion)Trial: NCT06362369 2024-08-23 → 2027-12-31 (primary completion)Trial: NCT06284564 2024-08-07 → 2026-10-01 (primary completion)Trial: NCT06532149 2024-08-05 → 2026-09-05 (primary completion)Trial: NCT05898828 2024-08-02 → 2024-08-02 (primary completion)Trial: NCT06495125 2024-07-31 → 2029-03-17 (primary completion)Trial: NCT06421311 2024-07-30 → 2025-04-04 (primary completion)Trial: NCT05896839 2024-07-24 → 2027-01-31 (primary completion)Trial: NCT06638931 2024-07-16 → 2026-07-31 (primary completion)Trial: NCT06029270 2024-07-15 → 2029-04-30 (primary completion)Trial: NCT06466798 2024-07-15 → 2027-07-01 (primary completion)Trial: NCT06264180 2024-07-11 → 2030-09-30 (primary completion)Trial: NCT06208657 2024-07-10 → 2030-12-31 (primary completion)Trial: NCT06554613 2024-07-02 → 2026-12-01 (primary completion)Trial: NCT06302426 2024-07-01 → 2026-10-30 (primary completion)Trial: NCT05153304 2024-06-30 → 2026-06-30 (primary completion)Trial: NCT06064097 2024-06-25 → 2026-12-31 (primary completion)Trial: NCT06203600 2024-06-24 → 2027-10-31 (primary completion)Trial: NCT06377111 2024-06-24 → 2027-08-31 (primary completion)Trial: NCT06288191 2024-06-21 → 2026-09-30 (primary completion)Trial: NCT06399419 2024-06-19 → 2026-10-19 (primary completion)Trial: NCT06112314 2024-06-05 → 2027-10-16 (primary completion)Trial: NCT06771674 2024-06-05 → 2025-02-28 (primary completion)Trial: NCT06274437 2024-06-02 → 2027-09-30 (primary completion)Trial: NCT06357858 2024-06-01 → 2025-02-28 (primary completion)Trial: NCT06295159 2024-05-17 → 2028-11-30 (primary completion)Trial: NCT06265285 2024-04-30 → 2026-12-31 (primary completion)Trial: NCT06253611 2024-04-16 → 2027-09-30 (primary completion)Trial: NCT06364631 2024-04-12 → 2032-05-05 (primary completion)Trial: NCT06304597 2024-04-01 → 2025-03-01 (primary completion)Trial: NCT07436390 2024-03-31 → 2024-03-31 (primary completion)Trial: NCT06247540 2024-03-29 → 2029-12-29 (primary completion)Trial: NCT07523763 2024-03-22 → 2025-12-31 (primary completion)Trial: NCT06640530 2024-03-21 → 2025-12-31 (primary completion)Trial: NCT06097975 2024-03-15 → 2025-06-01 (primary completion)Trial: NCT06151236 2024-03-11 → 2026-12-31 (primary completion)Trial: NCT06240143 2024-03-08 → 2029-07-31 (primary completion)Trial: NCT06250335 2024-03-01 → 2027-01-23 (primary completion)FDA approval — 2005-12-02 FDA approved Hylenex Recombinant (hyaluronidase) (BLA 021859) Sponsor: HALOZYME THERAP. Class: Type 1 - New Molecular Entity.FDA approval (supplemental) — 2006-06-09 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Labeling (BLA 021859 S-2) Sponsor: HALOZYME THERAP. Class: Labeling.FDA approval (supplemental) — 2008-10-01 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Labeling (BLA 021859 S-5) Sponsor: HALOZYME THERAP. Class: Labeling.FDA approval (supplemental) — 2009-12-11 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Labeling (BLA 021859 S-6) Sponsor: HALOZYME THERAP. Class: Labeling.FDA approval (supplemental) — 2012-03-01 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Labeling (BLA 021859 S-9) Sponsor: HALOZYME THERAP. Class: Labeling.FDA approval (supplemental) — 2012-03-20 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Labeling (BLA 021859 S-15) Sponsor: HALOZYME THERAP. Class: Labeling.FDA approval (supplemental) — 2013-07-23 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Manufacturing (CMC) (BLA 021859 S-18) Sponsor: HALOZYME THERAP. Class: Manufacturing (CMC).FDA approval (supplemental) — 2014-05-06 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Manufacturing (CMC) (BLA 021859 S-20) Sponsor: HALOZYME THERAP. Class: Manufacturing (CMC).FDA approval (supplemental) — 2014-10-16 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Manufacturing (CMC) (BLA 021859 S-19) Sponsor: HALOZYME THERAP. Class: Manufacturing (CMC).FDA approval — 2014-12-22 FDA approved Opdivo (nivolumab) (BLA 125554) Sponsor: BRISTOL MYERS SQUIBB. Class: Type 1 - New Molecular Entity.FDA approval (supplemental) — 2015-04-14 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-4) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2015-04-14 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-3) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2015-04-17 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Manufacturing (CMC) (BLA 021859 S-21) Sponsor: HALOZYME THERAP. Class: Manufacturing (CMC).FDA approval (supplemental) — 2015-07-27 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Manufacturing (CMC) (BLA 021859 S-22) Sponsor: HALOZYME THERAP. Class: Manufacturing (CMC).FDA approval (supplemental) — 2015-09-30 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-2) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2015-10-09 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-5) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2015-11-23 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-12) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2015-11-23 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-1) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2016-01-21 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Labeling (BLA 021859 S-23) Sponsor: HALOZYME THERAP. Class: Labeling.FDA approval (supplemental) — 2016-01-23 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-7) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2016-05-17 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-19) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2016-06-21 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Manufacturing (CMC) (BLA 021859 S-25) Sponsor: HALOZYME THERAP. Class: Manufacturing (CMC).FDA approval (supplemental) — 2016-07-28 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Manufacturing (CMC) (BLA 021859 S-24) Sponsor: HALOZYME THERAP. Class: Manufacturing (CMC).FDA approval (supplemental) — 2016-09-13 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-17) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2016-09-13 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-18) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2016-10-04 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-16) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2016-11-10 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-22) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2017-02-02 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-24) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2017-04-25 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-31) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2017-06-22 FDA approved supplemental application for Rituxan Hycela (rituximab and hyaluronidase) — Type 5 - New Formulation or New Manufacturer (BLA 761064 S-1) Sponsor: GENENTECH INC. Class: Type 5 - New Formulation or New Manufacturer.FDA approval — 2017-06-22 FDA approved Rituxan Hycela (rituximab and hyaluronidase) (BLA 761064) Sponsor: GENENTECH INC. Class: Type 5 - New Formulation or New Manufacturer.FDA approval (supplemental) — 2017-07-31 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-34) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2017-09-06 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-40) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2017-09-22 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-41) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2017-12-20 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-55) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-01-09 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-36) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-01-09 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-35) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-01-09 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-37) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-01-09 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-39) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-01-09 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-38) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-02-13 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-56) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2018-02-15 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-45) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-02-15 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-44) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-61) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-49) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-48) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-62) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-66) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-52) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-51) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-65) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-64) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-03-05 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-50) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-04-16 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-58) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-07-10 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-63) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-08-16 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-67) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2018-11-15 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-69) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2019-02-01 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-72) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval — 2019-02-28 FDA approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) (BLA 761106) Sponsor: GENENTECH INC. Class: Type 5 - New Formulation or New Manufacturer.FDA approval (supplemental) — 2019-03-07 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-42) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2019-04-18 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-70) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2019-05-02 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-73) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2019-09-18 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-75) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2019-12-19 FDA approved supplemental application for Rituxan Hycela (rituximab and hyaluronidase) — Labeling (BLA 761064 S-9) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2020-03-10 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-78) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval — 2020-05-01 FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) (BLA 761145) Sponsor: JANSSEN BIOTECH. Class: Type 3 - New Dosage Form and Type 4 - New Combination.FDA approval (supplemental) — 2020-05-05 FDA approved supplemental application for Rituxan Hycela (rituximab and hyaluronidase) — Labeling (BLA 761064 S-10) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2020-05-05 FDA approved supplemental application for Rituxan Hycela (rituximab and hyaluronidase) — Labeling (BLA 761064 S-8) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2020-05-15 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-80) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2020-05-26 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-82) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2020-06-10 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-81) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2020-06-23 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-83) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval — 2020-06-29 FDA approved Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) (BLA 761170) Sponsor: GENENTECH INC. Class: Type 4 - New Combination.FDA approval (supplemental) — 2020-09-18 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-84) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2020-09-18 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-85) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2020-09-25 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-86) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2020-10-02 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-89) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2020-11-10 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-71) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2020-12-29 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-95) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2021-01-11 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-1) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2021-01-15 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-2) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2021-01-22 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-90) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2021-02-08 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Labeling (BLA 761145 S-8) Sponsor: JANSSEN BIOTECH. Class: Labeling.FDA approval (supplemental) — 2021-03-12 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Labeling (BLA 761145 S-5) Sponsor: JANSSEN BIOTECH. Class: Labeling.FDA approval (supplemental) — 2021-03-30 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-98) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2021-04-16 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-91) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2021-05-20 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-92) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2021-06-10 FDA approved supplemental application for Rituxan Hycela (rituximab and hyaluronidase) — Labeling (BLA 761064 S-13) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2021-07-09 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-7) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2021-07-15 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-99) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2021-07-23 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-107) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2021-08-19 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-97) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2021-11-30 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-9) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2022-01-21 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Labeling (BLA 761145 S-12) Sponsor: JANSSEN BIOTECH. Class: Labeling.FDA approval (supplemental) — 2022-02-25 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-109) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2022-03-04 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-112) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval — 2022-03-18 FDA approved Opdualag (nivolumab and relatlimab-rmbw) (BLA 761234) Sponsor: BRISTOL MYERS SQUIBB. Class: Type 1 - New Molecular Entity.FDA approval (supplemental) — 2022-05-11 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-108) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2022-05-27 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-105) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2022-05-27 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-106) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2022-07-14 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-114) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2022-11-02 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Labeling (BLA 761145 S-18) Sponsor: JANSSEN BIOTECH. Class: Labeling.FDA approval (supplemental) — 2023-02-15 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-117) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2023-02-15 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-118) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2023-02-15 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-119) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval — 2023-06-20 FDA approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) (BLA 761304) Sponsor: ARGENX BV.FDA approval (supplemental) — 2023-10-13 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-121) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2023-12-12 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Labeling (BLA 761304 S-2) Sponsor: ARGENX BV. Class: Labeling.FDA approval (supplemental) — 2024-01-12 FDA approved supplemental application for Hylenex Recombinant (hyaluronidase) — Labeling (BLA 021859 S-31) Sponsor: HALOZYME THERAP. Class: Labeling.FDA approval (supplemental) — 2024-01-26 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-122) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2024-03-06 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-128) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2024-03-06 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-125) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2024-03-06 FDA approved supplemental application for Opdualag (nivolumab and relatlimab-rmbw) — Labeling (BLA 761234 S-6) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2024-06-18 FDA approved supplemental application for Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) — Efficacy (BLA 761106 S-10) Sponsor: GENENTECH INC. Class: Efficacy.FDA approval (supplemental) — 2024-06-21 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Efficacy (BLA 761304 S-5) Sponsor: ARGENX BV. Class: Efficacy.FDA approval (supplemental) — 2024-06-21 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Labeling (BLA 761304 S-6) Sponsor: ARGENX BV. Class: Labeling.FDA approval (supplemental) — 2024-07-30 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-25) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2024-08-08 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Efficacy (BLA 761304 S-3) Sponsor: ARGENX BV. Class: Efficacy.FDA approval — 2024-09-12 FDA approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) (BLA 761347) Sponsor: GENENTECH INC. Class: Type 3 - New Dosage Form.FDA approval — 2024-09-13 FDA approved Ocrevus Zunovo (ocrelizumab and hyaluronidase) (BLA 761371) Sponsor: GENENTECH INC. Class: Type 3 - New Dosage Form.FDA approval (supplemental) — 2024-10-03 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-127) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2024-11-22 FDA approved supplemental application for Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) — Efficacy (BLA 761170 S-7) Sponsor: GENENTECH INC. Class: Efficacy.FDA approval — 2024-12-27 FDA approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) (BLA 761381) Sponsor: BRISTOL-MYERS SQUIBB. Class: Type 3 - New Dosage Form.FDA approval (supplemental) — 2025-04-08 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-132) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2025-04-10 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Efficacy (BLA 761304 S-8) Sponsor: ARGENX BV. Class: Efficacy.FDA approval (supplemental) — 2025-04-11 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-129) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2025-05-23 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-133) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2025-05-23 FDA approved supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) — Labeling (BLA 761381 S-8) Sponsor: BRISTOL-MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2025-07-01 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-131) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2025-08-18 FDA approved supplemental application for Ocrevus Zunovo (ocrelizumab and hyaluronidase) — Labeling (BLA 761371 S-1) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2025-08-18 FDA approved supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Labeling (BLA 761347 S-2) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2025-10-02 FDA approved supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Efficacy (BLA 761347 S-3) Sponsor: GENENTECH INC. Class: Efficacy.FDA approval (supplemental) — 2025-10-17 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Efficacy (BLA 761304 S-10) Sponsor: ARGENX BV. Class: Efficacy.FDA approval (supplemental) — 2025-10-27 FDA approved supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) — Efficacy (BLA 761381 S-1) Sponsor: BRISTOL-MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2025-10-27 FDA approved supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) — Efficacy (BLA 761381 S-2) Sponsor: BRISTOL-MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2025-11-06 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-29) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2025-11-14 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Labeling (BLA 761145 S-35) Sponsor: JANSSEN BIOTECH. Class: Labeling.FDA approval (supplemental) — 2025-11-17 FDA approved supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Labeling (BLA 761347 S-5) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2025-11-19 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-32) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2025-11-24 FDA approved supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) — Efficacy (BLA 761381 S-5) Sponsor: BRISTOL-MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2025-11-24 FDA approved supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Efficacy (BLA 761347 S-4) Sponsor: GENENTECH INC. Class: Efficacy.FDA approval — 2025-12-17 FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj (human recombinant)) (BLA 761433) Sponsor: JANSSEN BIOTECH. Class: Type 5 - New Formulation or New Manufacturer.FDA approval (supplemental) — 2026-01-27 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Efficacy (BLA 761145 S-28) Sponsor: JANSSEN BIOTECH. Class: Efficacy.FDA approval (supplemental) — 2026-02-12 FDA approved supplemental application for Darzalex Faspro (daratumumab and hyaluronidase-fihj (human recombinant)) — Labeling (BLA 761145 S-39) Sponsor: JANSSEN BIOTECH. Class: Labeling.FDA approval — 2026-02-13 FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj (human recombinant)) (BLA 761484) Sponsor: JANSSEN BIOTECH. Class: Type 5 - New Formulation or New Manufacturer.FDA approval (supplemental) — 2026-02-26 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Labeling (BLA 761304 S-19) Sponsor: ARGENX BV. Class: Labeling.FDA approval (supplemental) — 2026-03-20 FDA approved supplemental application for Opdivo (nivolumab) — Efficacy (BLA 125554 S-135) Sponsor: BRISTOL MYERS SQUIBB. Class: Efficacy.FDA approval (supplemental) — 2026-05-08 FDA approved supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) — Efficacy (BLA 761304 S-18) Sponsor: ARGENX BV. Class: Efficacy.FDA approval (supplemental) — 2026-05-12 FDA approved supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) — Labeling (BLA 761381 S-12) Sponsor: BRISTOL-MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2026-05-12 FDA approved supplemental application for Opdivo (nivolumab) — Labeling (BLA 125554 S-136) Sponsor: BRISTOL MYERS SQUIBB. Class: Labeling.FDA approval (supplemental) — 2026-05-12 FDA approved supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Labeling (BLA 761347 S-9) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2026-05-15 FDA approved supplemental application for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Efficacy (BLA 761347 S-8) Sponsor: GENENTECH INC. Class: Efficacy.FDA approval (supplemental) — 2026-05-18 FDA approved supplemental application for Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) — Labeling (BLA 761106 S-14) Sponsor: GENENTECH INC. Class: Labeling.FDA approval (supplemental) — 2026-05-18 FDA approved supplemental application for Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) — Labeling (BLA 761170 S-16) Sponsor: GENENTECH INC. Class: Labeling.Label revision — 2026-05-21 Boxed warning present on label on Phesgo label (effective 2026-05-21) WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning. Cardiomyopathy: PHESGO administrationLabel revision — 2026-05-29 Boxed warning present on label on Herceptin Hylecta label (effective 2026-05-29) WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning. Cardiomyopathy: HERCEPTIN HYLECTA canRecall — 2024-09-11 HYLENEX RECOMBINANT recall — Class II: cGMP Deviations: Temperature excursion Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozyme, Inc., 12390 El Camino Real San Diego California 92130, Distributed by Antares Pharma, Inc., EwingRecall — 2025-10-21 OPDUALAG recall — Class II: Lack of Assurance of Sterility. Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11Results posted — 2022-12-19 Trial results posted: NCT03635983 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaResults posted — 2022-12-20 Trial results posted: NCT03370276 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaResults posted — 2022-12-28 Trial results posted: NCT03126110 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalResults posted — 2022-12-29 Trial results posted: NCT02923531 Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaResults posted — 2023-01-10 Trial results posted: NCT02304458 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasResults posted — 2023-01-10 Trial results posted: NCT04088500 A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaResults posted — 2023-01-25 Trial results posted: NCT03684811 A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationResults posted — 2023-01-26 Trial results posted: NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast CancerResults posted — 2023-01-31 Trial results posted: NCT02154490 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerResults posted — 2023-02-02 Trial results posted: NCT03430791 Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaResults posted — 2023-02-02 Trial results posted: NCT01714739 A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab AnResults posted — 2023-02-06 Trial results posted: NCT02864251 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With EpResults posted — 2023-02-08 Trial results posted: NCT03468985 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerResults posted — 2023-02-15 Trial results posted: NCT03663166 Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)Results posted — 2023-02-17 Trial results posted: NCT03121534 Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationResults posted — 2023-02-28 Trial results posted: NCT03251924 A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in PatientResults posted — 2023-03-06 Trial results posted: NCT02598960 An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients Results posted — 2023-03-07 Trial results posted: NCT02581631 An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LResults posted — 2023-03-08 Trial results posted: NCT03435640 REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesResults posted — 2023-03-13 Trial results posted: NCT02983045 A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With SeleResults posted — 2023-03-17 Trial results posted: NCT02771626 Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung CancerResults posted — 2023-03-23 Trial results posted: NCT03057795 Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaResults posted — 2023-03-24 Trial results posted: NCT04730349 A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or TrResults posted — 2023-03-27 Trial results posted: NCT02726581 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaResults posted — 2023-03-28 Trial results posted: NCT03785925 A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic UResults posted — 2023-03-30 Trial results posted: NCT03406715 Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)Results posted — 2023-04-05 Trial results posted: NCT02754141 An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabResults posted — 2023-04-11 Trial results posted: NCT03729245 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase IResults posted — 2023-04-18 Trial results posted: NCT02426892 Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid TumorsResults posted — 2023-04-21 Trial results posted: NCT04410445 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma iResults posted — 2023-04-24 Trial results posted: NCT03168464 Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)Results posted — 2023-04-24 Trial results posted: NCT02985957 A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMatResults posted — 2023-04-26 Trial results posted: NCT02327078 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHOResults posted — 2023-05-01 Trial results posted: NCT03033576 Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaResults posted — 2023-05-18 Trial results posted: NCT03668119 A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor MutatioResults posted — 2023-05-19 Trial results posted: NCT03071406 Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell CarcinomaResults posted — 2023-05-26 Trial results posted: NCT03417154 Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSResults posted — 2023-06-01 Trial results posted: NCT03519256 A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG UnresponsivResults posted — 2023-06-06 Trial results posted: NCT03001882 An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small CResults posted — 2023-06-09 Trial results posted: NCT03436862 Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskResults posted — 2023-06-09 Trial results posted: NCT02935634 A Study to Test Combination Treatments in Participants With Advanced Gastric CancerResults posted — 2023-06-09 Trial results posted: NCT04166383 VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)Results posted — 2023-06-12 Trial results posted: NCT02712905 An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesResults posted — 2023-06-12 Trial results posted: NCT04122625 Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143Results posted — 2023-06-13 Trial results posted: NCT02903381 A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaResults posted — 2023-06-15 Trial results posted: NCT02329847 A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in PaResults posted — 2023-06-15 Trial results posted: NCT03711058 Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-Results posted — 2023-06-23 Trial results posted: NCT03382561 Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerResults posted — 2023-06-27 Trial results posted: NCT03816332 Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersResults posted — 2023-06-28 Trial results posted: NCT03495713 Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSResults posted — 2023-07-03 Trial results posted: NCT03404960 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyResults posted — 2023-07-10 Trial results posted: NCT03222076 Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerResults posted — 2023-07-10 Trial results posted: NCT03190265 Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerResults posted — 2023-07-11 Trial results posted: NCT03785210 Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Results posted — 2023-07-27 Trial results posted: NCT04099251 Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaResults posted — 2023-08-04 Trial results posted: NCT03421652 Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for ChemoResults posted — 2023-08-18 Trial results posted: NCT03502330 APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaResults posted — 2023-08-21 Trial results posted: NCT04119336 Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaResults posted — 2023-08-22 Trial results posted: NCT03695250 BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerResults posted — 2023-08-24 Trial results posted: NCT03606174 A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic UrothelialResults posted — 2023-08-28 Trial results posted: NCT02658890 An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and IpilimuResults posted — 2023-08-29 Trial results posted: NCT04208958 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerResults posted — 2023-09-21 Trial results posted: NCT02831933 Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaResults posted — 2023-09-21 Trial results posted: NCT02439450 A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerResults posted — 2023-10-03 Trial results posted: NCT03554317 COMbination of Bipolar Androgen Therapy and NivolumabResults posted — 2023-10-26 Trial results posted: NCT03502746 Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated MesotheliomaResults posted — 2023-11-29 Trial results posted: NCT03472586 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the LiverResults posted — 2023-12-05 Trial results posted: NCT03123783 CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabResults posted — 2023-12-06 Trial results posted: NCT03229278 Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaResults posted — 2023-12-06 Trial results posted: NCT03600350 pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerResults posted — 2023-12-13 Trial results posted: NCT04899921 Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsResults posted — 2023-12-20 Trial results posted: NCT03894891 Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerResults posted — 2023-12-21 Trial results posted: NCT03646123 Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaResults posted — 2023-12-29 Trial results posted: NCT03749460 Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersResults posted — 2024-01-03 Trial results posted: NCT05041062 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaResults posted — 2024-01-09 Trial results posted: NCT03420521 Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsResults posted — 2024-01-17 Trial results posted: NCT03651271 Nivolumab With or Without Ipilimumab in Advanced Metastatic CancerResults posted — 2024-01-18 Trial results posted: NCT03146650 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerResults posted — 2024-01-23 Trial results posted: NCT03484819 Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary MediastinaResults posted — 2024-01-30 Trial results posted: NCT03570619 Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsResults posted — 2024-02-22 Trial results posted: NCT03461952 Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)Results posted — 2024-02-28 Trial results posted: NCT05005273 A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small CResults posted — 2024-03-05 Trial results posted: NCT02247349 BMS-986012 in Relapsed/Refractory SCLCResults posted — 2024-03-12 Trial results posted: NCT04109066 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-riskResults posted — 2024-03-15 Trial results posted: NCT03519308 A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerResults posted — 2024-03-20 Trial results posted: NCT02259621 Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCResults posted — 2024-03-20 Trial results posted: NCT02420912 Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small LymphocytResults posted — 2024-04-01 Trial results posted: NCT03342911 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by SResults posted — 2024-04-04 Trial results posted: NCT02978443 A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabResults posted — 2024-04-04 Trial results posted: NCT03310619 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesResults posted — 2024-04-05 Trial results posted: NCT02519322 Neoadjuvant and Adjuvant Checkpoint BlockadeResults posted — 2024-04-10 Trial results posted: NCT04057365 Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)Results posted — 2024-04-12 Trial results posted: NCT03835533 Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsResults posted — 2024-04-18 Trial results posted: NCT03311334 A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsResults posted — 2024-04-22 Trial results posted: NCT02954991 Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerResults posted — 2024-04-22 Trial results posted: NCT03692325 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous LeukoplakiaResults posted — 2024-04-25 Trial results posted: NCT03055013 Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyResults posted — 2024-04-29 Trial results posted: NCT03711188 A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced MelanomaResults posted — 2024-05-01 Trial results posted: NCT04396860 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide andResults posted — 2024-05-03 Trial results posted: NCT01928576 Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.Results posted — 2024-05-16 Trial results posted: NCT03451331 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic UrotheliResults posted — 2024-05-16 Trial results posted: NCT04331067 Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerResults posted — 2024-05-20 Trial results posted: NCT03562507 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaResults posted — 2024-05-21 Trial results posted: NCT03246958 Nivolumab Plus Ipilimumab in Thyroid CancerResults posted — 2024-05-23 Trial results posted: NCT04655157 Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in CombinatioResults posted — 2024-05-29 Trial results posted: NCT02350764 Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCsResults posted — 2024-05-30 Trial results posted: NCT04319224 Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (Results posted — 2024-05-31 Trial results posted: NCT02933255 PROSTVAC in Combination With Nivolumab in Men With Prostate CancerResults posted — 2024-06-06 Trial results posted: NCT03817125 Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionResults posted — 2024-06-11 Trial results posted: NCT01716806 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Results posted — 2024-06-20 Trial results posted: NCT03418922 A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaResults posted — 2024-06-25 Trial results posted: NCT03906071 Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerResults posted — 2024-06-27 Trial results posted: NCT04209114 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer ThaResults posted — 2024-06-27 Trial results posted: NCT03558087 Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder SparingResults posted — 2024-06-28 Trial results posted: NCT02949843 Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsResults posted — 2024-07-01 Trial results posted: NCT03631641 Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial ColectomyResults posted — 2024-07-16 Trial results posted: NCT04159896 ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerResults posted — 2024-07-18 Trial results posted: NCT03195491 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaResults posted — 2024-07-22 Trial results posted: NCT04100018 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerResults posted — 2024-07-23 Trial results posted: NCT03336216 A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerResults posted — 2024-07-23 Trial results posted: NCT04704154 A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With SoliResults posted — 2024-07-23 Trial results posted: NCT03092674 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed AcuResults posted — 2024-07-23 Trial results posted: NCT04025879 A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant TResults posted — 2024-07-24 Trial results posted: NCT03493932 Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeResults posted — 2024-08-12 Trial results posted: NCT03620019 Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaResults posted — 2024-08-13 Trial results posted: NCT04778904 First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBVResults posted — 2024-08-21 Trial results posted: NCT03639935 Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyResults posted — 2024-08-22 Trial results posted: NCT03425331 Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCResults posted — 2024-09-03 Trial results posted: NCT03552380 Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaResults posted — 2024-09-05 Trial results posted: NCT03800602 Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal CancerResults posted — 2024-09-19 Trial results posted: NCT03453164 Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)Results posted — 2024-09-19 Trial results posted: NCT05200143 Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaResults posted — 2024-09-19 Trial results posted: NCT03521570 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell CancerResults posted — 2024-09-19 Trial results posted: NCT04458909 Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With GeResults posted — 2024-10-08 Trial results posted: NCT03583086 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsResults posted — 2024-10-08 Trial results posted: NCT04567615 A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncolResults posted — 2024-10-09 Trial results posted: NCT03016871 Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HLResults posted — 2024-10-09 Trial results posted: NCT03999749 A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With UnresectaResults posted — 2024-10-16 Trial results posted: NCT02879695 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-LymphoblaResults posted — 2024-10-16 Trial results posted: NCT03038672 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasResults posted — 2024-10-22 Trial results posted: NCT04277442 Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaResults posted — 2024-10-23 Trial results posted: NCT02833233 A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast CancerResults posted — 2024-10-24 Trial results posted: NCT02532231 Nivolumab in AML in Remission at High Risk for RelapseResults posted — 2024-10-26 Trial results posted: NCT03296137 Adoptive Cell Therapy Across Cancer DiagnosesResults posted — 2024-10-29 Trial results posted: NCT03586999 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasResults posted — 2024-10-31 Trial results posted: NCT03929029 Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaResults posted — 2024-11-04 Trial results posted: NCT02397720 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaResults posted — 2024-11-08 Trial results posted: NCT02046733 Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseResults posted — 2024-11-12 Trial results posted: NCT03575793 A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerResults posted — 2024-11-19 Trial results posted: NCT03015740 Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerResults posted — 2024-11-21 Trial results posted: NCT03878979 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNResults posted — 2024-11-25 Trial results posted: NCT02702492 PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)Results posted — 2024-11-26 Trial results posted: NCT04340193 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With IntResults posted — 2024-11-27 Trial results posted: NCT04091750 Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaResults posted — 2024-12-03 Trial results posted: NCT03487666 OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual DiseaseResults posted — 2024-12-04 Trial results posted: NCT03081689 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsResults posted — 2024-12-10 Trial results posted: NCT02754726 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaResults posted — 2024-12-18 Trial results posted: NCT03138512 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who UnderwentResults posted — 2024-12-27 Trial results posted: NCT03241745 A Study of Nivolumab in Selected Uterine Cancer PatientsResults posted — 2025-01-09 Trial results posted: NCT03262779 Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.Results posted — 2025-01-13 Trial results posted: NCT03452579 Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMResults posted — 2025-01-13 Trial results posted: NCT03980925 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the GastroenteropancreaticResults posted — 2025-01-14 Trial results posted: NCT04187833 Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesResults posted — 2025-01-14 Trial results posted: NCT04382664 UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of MelanomaResults posted — 2025-01-22 Trial results posted: NCT04350463 A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced CancersResults posted — 2025-01-22 Trial results posted: NCT02960230 H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other GliomasResults posted — 2025-01-24 Trial results posted: NCT03406871 Regorafenib and Nivolumab Simultaneous Combination TherapyResults posted — 2025-01-27 Trial results posted: NCT03523572 Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerResults posted — 2025-01-28 Trial results posted: NCT03642067 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerResults posted — 2025-01-29 Trial results posted: NCT03447470 Study to Evaluate the Safety and Tolerability of RXC004 in Advanced MalignanciesResults posted — 2025-01-31 Trial results posted: NCT04197310 Cabozantinib and Nivolumab for Carcinoid TumorsResults posted — 2025-02-03 Trial results posted: NCT03161379 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic CancerResults posted — 2025-02-06 Trial results posted: NCT04056910 Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsResults posted — 2025-02-10 Trial results posted: NCT02927769 A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory Results posted — 2025-02-11 Trial results posted: NCT03439891 Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver CancerResults posted — 2025-02-13 Trial results posted: NCT04552223 Nivolumab Plus Relatlimab in Patients With Metastatic Uveal MelanomaResults posted — 2025-02-17 Trial results posted: NCT03190174 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersResults posted — 2025-02-20 Trial results posted: NCT03047928 Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic MelanomaResults posted — 2025-02-20 Trial results posted: NCT03656718 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)Results posted — 2025-02-25 Trial results posted: NCT04322643 Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaResults posted — 2025-02-27 Trial results posted: NCT05297565 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionResults posted — 2025-03-05 Trial results posted: NCT03158129 Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerResults posted — 2025-03-07 Trial results posted: NCT05061017 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide Results posted — 2025-03-11 Trial results posted: NCT03285321 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)Results posted — 2025-03-11 Trial results posted: NCT03727061 Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced oResults posted — 2025-03-17 Trial results posted: NCT04761198 A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsResults posted — 2025-03-18 Trial results posted: NCT05543629 A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerResults posted — 2025-03-18 Trial results posted: NCT04623775 A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line TreatmentResults posted — 2025-03-25 Trial results posted: NCT03377023 Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerResults posted — 2025-03-30 Trial results posted: NCT05834348 A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.Results posted — 2025-04-02 Trial results posted: NCT04698187 CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaResults posted — 2025-04-03 Trial results posted: NCT04938232 Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLResults posted — 2025-04-16 Trial results posted: NCT04907539 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, MicrosatelliResults posted — 2025-04-16 Trial results posted: NCT06094296 A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell LuResults posted — 2025-04-20 Trial results posted: NCT02913313 A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsResults posted — 2025-04-22 Trial results posted: NCT03719131 Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyResults posted — 2025-04-24 Trial results posted: NCT03110107 First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorResults posted — 2025-04-29 Trial results posted: NCT03689699 Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)Results posted — 2025-04-30 Trial results posted: NCT06003075 Induction Chemo-Nivo in Unresectable Stage III NSCLCResults posted — 2025-05-02 Trial results posted: NCT03952585 De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-PositResults posted — 2025-05-06 Trial results posted: NCT03107182 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck CancerResults posted — 2025-05-06 Trial results posted: NCT04526730 Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsResults posted — 2025-05-11 Trial results posted: NCT03944915 De-Escalation Therapy for Human Papillomavirus Negative DiseaseResults posted — 2025-06-10 Trial results posted: NCT05169684 A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant ProstaResults posted — 2025-06-12 Trial results posted: NCT03907488 Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV ClassiResults posted — 2025-06-19 Trial results posted: NCT03400332 A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersResults posted — 2025-06-24 Trial results posted: NCT03522246 A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-BasResults posted — 2025-06-25 Trial results posted: NCT03815942 VAccination in Early and ADvanced Prostate caNCErResults posted — 2025-06-26 Trial results posted: NCT04282109 Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for CisplatResults posted — 2025-07-10 Trial results posted: NCT03117309 Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaResults posted — 2025-07-11 Trial results posted: NCT04513522 A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in Results posted — 2025-07-15 Trial results posted: NCT04493203 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaResults posted — 2025-07-18 Trial results posted: NCT05116202 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)Results posted — 2025-07-22 Trial results posted: NCT03547999 A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRCResults posted — 2025-07-22 Trial results posted: NCT02553642 Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated WitResults posted — 2025-07-24 Trial results posted: NCT04026412 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned Results posted — 2025-07-24 Trial results posted: NCT04891770 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B Results posted — 2025-07-25 Trial results posted: NCT02681302 Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceResults posted — 2025-08-06 Trial results posted: NCT03697564 Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic CancerResults posted — 2025-08-06 Trial results posted: NCT03739619 Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaResults posted — 2025-08-12 Trial results posted: NCT04611126 T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerResults posted — 2025-08-12 Trial results posted: NCT03636477 A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102Results posted — 2025-09-05 Trial results posted: NCT04695977 CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaResults posted — 2025-09-10 Trial results posted: NCT03937219 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CResults posted — 2025-09-15 Trial results posted: NCT03195478 A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsResults posted — 2025-09-16 Trial results posted: NCT04149574 A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants WResults posted — 2025-09-18 Trial results posted: NCT03446040 An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are AdvResults posted — 2025-09-18 Trial results posted: NCT03036098 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in TrResults posted — 2025-09-22 Trial results posted: NCT04008030 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient MismResults posted — 2025-09-23 Trial results posted: NCT02408861 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That AreResults posted — 2025-10-03 Trial results posted: NCT05407675 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in ParticiResults posted — 2025-10-09 Trial results posted: NCT03184870 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsResults posted — 2025-10-10 Trial results posted: NCT03595124 A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Results posted — 2025-10-14 Trial results posted: NCT03573947 Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCResults posted — 2025-10-16 Trial results posted: NCT04050462 Nivolumab Combined With BMS-986253 in HCC PatientsResults posted — 2025-10-30 Trial results posted: NCT02477826 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, CompareResults posted — 2025-10-31 Trial results posted: NCT03914300 Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerResults posted — 2025-11-03 Trial results posted: NCT04205409 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MaligResults posted — 2025-11-03 Trial results posted: NCT03557359 Nivolumab for Recurrent or Progressive IDH Mutant GliomasResults posted — 2025-11-06 Trial results posted: NCT02275533 Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN TrialResults posted — 2025-11-06 Trial results posted: NCT02060188 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadResults posted — 2025-11-10 Trial results posted: NCT02823990 TG4010 and Nivolumab in Patients With Lung CancerResults posted — 2025-11-12 Trial results posted: NCT03021993 Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity CancerResults posted — 2025-11-18 Trial results posted: NCT03369223 A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsResults posted — 2025-11-24 Trial results posted: NCT03718767 Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeResults posted — 2025-12-03 Trial results posted: NCT04021043 BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic LResults posted — 2025-12-03 Trial results posted: NCT03377361 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With PreviousResults posted — 2025-12-03 Trial results posted: NCT03388632 Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersResults posted — 2025-12-12 Trial results posted: NCT03347838 Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former SmokersResults posted — 2025-12-12 Trial results posted: NCT04079712 Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsResults posted — 2025-12-17 Trial results posted: NCT04349267 Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsResults posted — 2025-12-17 Trial results posted: NCT04688658 Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaResults posted — 2025-12-18 Trial results posted: NCT03172624 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerResults posted — 2025-12-24 Trial results posted: NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents inResults posted — 2026-01-06 Trial results posted: NCT01968109 An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in theResults posted — 2026-01-08 Trial results posted: NCT04326257 Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyResults posted — 2026-01-08 Trial results posted: NCT05002569 A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelaResults posted — 2026-01-12 Trial results posted: NCT03267498 Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)Results posted — 2026-01-20 Trial results posted: NCT03994601 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersResults posted — 2026-01-22 Trial results posted: NCT03829722 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck CancerResults posted — 2026-01-26 Trial results posted: NCT02648997 An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaResults posted — 2026-01-30 Trial results posted: NCT04187404 A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaResults posted — 2026-02-12 Trial results posted: NCT05921760 Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarciResults posted — 2026-02-13 Trial results posted: NCT03785873 Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerResults posted — 2026-02-13 Trial results posted: NCT03388190 METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinResults posted — 2026-02-17 Trial results posted: NCT02523469 ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung CancerResults posted — 2026-02-18 Trial results posted: NCT02224781 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in TreatingResults posted — 2026-02-20 Trial results posted: NCT03366766 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung CancerResults posted — 2026-02-27 Trial results posted: NCT03358719 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute MResults posted — 2026-03-17 Trial results posted: NCT03799445 Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaResults posted — 2026-03-18 Trial results posted: NCT04902040 Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Results posted — 2026-03-20 Trial results posted: NCT04637594 Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyResults posted — 2026-03-27 Trial results posted: NCT04785820 A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Results posted — 2026-04-01 Trial results posted: NCT02873962 A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibResults posted — 2026-04-06 Trial results posted: NCT03459222 An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadResults posted — 2026-04-09 Trial results posted: NCT06101134 A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + RelatlResults posted — 2026-04-22 Trial results posted: NCT02314169 Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerResults posted — 2026-04-22 Trial results posted: NCT03981146 A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal CancerResults posted — 2026-04-29 Trial results posted: NCT03367741 Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerResults posted — 2026-05-05 Trial results posted: NCT04339738 Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaResults posted — 2026-05-05 Trial results posted: NCT05144529 A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCResults posted — 2026-05-06 Trial results posted: NCT03355560 Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive TherapyResults posted — 2026-05-08 Trial results posted: NCT03637543 Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate CancerResults posted — 2026-05-11 Trial results posted: NCT03767582 Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.Results posted — 2026-05-12 Trial results posted: NCT01703949 Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaResults posted — 2026-05-15 Trial results posted: NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate CancerResults posted — 2026-05-22 Trial results posted: NCT03646461 Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCResults posted — 2026-05-27 Trial results posted: NCT04126070 Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed TumorsResults posted — 2026-05-28 Trial results posted: NCT04514484 Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVResults posted — 2026-05-29 Trial results posted: NCT02073123 Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaResults posted — 2026-06-03 Trial results posted: NCT03958383 IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaResults posted — 2026-06-10 Trial results posted: NCT04879368 RegoNivo vs Standard of Care Chemotherapy in AGOCResults posted — 2026-06-16 Trial results posted: NCT03405155 Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by SurgeryResults posted — 2026-06-17 Trial results posted: NCT04702880 A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CanResults posted — 2026-06-24 Trial results posted: NCT04021108 Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic Results posted — 2026-06-26 Trial results posted: NCT05255601 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young AdulResults posted — 2026-06-29 Trial results posted: NCT03682276 Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaResults posted — 2026-07-02 Trial results posted: NCT04401995 Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. NivolumabResults posted — 2026-07-08 Trial results posted: NCT05715216 EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-Results posted — 2026-07-09 Trial results posted: NCT02009449 A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsPivotal publication — 2024-01-01 Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. (Lancet) Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant MelanomaPivotal publication — 2024-01-01 Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (N Engl J Med) Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaPivotal publication — 2024-01-01 Perioperative Nivolumab in Resectable Lung Cancer. (N Engl J Med) A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Pivotal publication — 2024-01-01 Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiN (Lancet) Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaPivotal publication — 2025-01-01 Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, rando (Lancet) CheckMate 9DW — A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaPivotal publication — 2025-01-01 Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. (N Engl J Med) Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)Pivotal publication — 2025-01-01 Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 tr (Lancet) CheckMate 8HW — A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) MPivotal publication — 2025-01-01 Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. (N Engl J Med) CheckMate 816 — A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)Pivotal publication — 2026-01-01 Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck (Lancet) NIVOPOSTOP — A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and NeckPivotal publication — 2026-01-01 Nivolumab for Resected Stage III or IV Melanoma at 9 Years. (N Engl J Med) CheckMate 238 — Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanomatoday (2026-07-17)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-07-17Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Nivolumab since 2005, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (205)

2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Upcoming & expected milestones

Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07460765
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06365619
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT04674683
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Can
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07546812
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06968988
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05601752
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07700979
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Par
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06319196
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04462406
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07430202
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advance
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT03635892
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07694986
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07444619
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With R
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05428007
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT02099058
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07576725
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07541170
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants
Primary completion· ClinicalTrials.gov
Primary completion: NCT06532149
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Primary completion· ClinicalTrials.gov
Primary completion: NCT07485166
Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases
Primary completion· ClinicalTrials.gov
NA primary completion: NCT02194738
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMI
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT02451982
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04106414
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Past events

2026
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04080804
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07492680
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Hom
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT04039607
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT02009449
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Results posted· ClinicalTrials.gov
Trial results posted: NCT05715216
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-
Results posted· ClinicalTrials.gov
Trial results posted: NCT04401995
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT03502733
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05867121
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04831320
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT03646617
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06365619
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT05568095
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT03110978
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Can
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05504642
Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT06639607
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Med
Results posted· ClinicalTrials.gov
Trial results posted: NCT03682276
Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT05255601
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adul
Results posted· ClinicalTrials.gov
Trial results posted: NCT04021108
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06049576
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT04702880
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Can
Results posted· ClinicalTrials.gov
Trial results posted: NCT03405155
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT05267626
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Met
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT06931613
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07476326
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07176975
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Differ
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05723055
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07546812
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT02451982
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07369791
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07529873
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04015778
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Results posted· ClinicalTrials.gov
Trial results posted: NCT02073123
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Results posted· ClinicalTrials.gov
Trial results posted: NCT03646461
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07420439
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05836571
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT01703949
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT03767582
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Results posted· ClinicalTrials.gov
Trial results posted: NCT03355560
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
Results posted· ClinicalTrials.gov
Trial results posted: NCT05144529
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07514767
Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07510334
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT06639607
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Med
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07338981
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07546812
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07527858
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07460765
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05112601
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07188896
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Results posted· ClinicalTrials.gov
Trial results posted: NCT03367741
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
Results posted· ClinicalTrials.gov
Trial results posted: NCT02314169
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
Results posted· ClinicalTrials.gov
Trial results posted: NCT03981146
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Results posted· ClinicalTrials.gov
Trial results posted: NCT06101134
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatl
Results posted· ClinicalTrials.gov
Trial results posted: NCT03459222
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07128680
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell C
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05817903
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07187869
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Can
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05280457
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccinatio
Results posted· ClinicalTrials.gov
Trial results posted: NCT04785820
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT07293351
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participa
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07401875
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07405164
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04817254
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) i
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07219459
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post A
Results posted· ClinicalTrials.gov
Trial results posted: NCT04902040
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted
Primary completion· ClinicalTrials.gov
NA primary completion: NCT04603248
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carci
Results posted· ClinicalTrials.gov
Trial results posted: NCT03799445
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05867121
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of
Trial started· ClinicalTrials.gov
Phase 2/Phase 3 trial started: NCT07221149
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06863311
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Trial started· ClinicalTrials.gov
Trial started: NCT07485166
Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT04495257
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT04323046
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05743270
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT04495257
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05308446
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Muta
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT05263050
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07432295
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Trial started· ClinicalTrials.gov
Trial started: NCT07394062
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06354387
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expressi
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06365619
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06319196
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Results posted· ClinicalTrials.gov
Trial results posted: NCT03358719
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute M
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT03383458
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ab
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT04709276
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.